Showing 1121-1130 of 1614 results for "".
- Epion Presents Survey on Keratoconus Highlighting Need for Accessible Treatmentshttps://modernod.com/news/epion-presents-survey-on-keratoconus-highlighting-urgent-need-for-accessible-treatments/2482518/Jonathan H. Talamo, MD, Chair of the Board at Epion Therapeutics, presented findings at the Eyecelerator@AAO 2024 conference on the current state of keratoconus (KC) management in the United States, highlighting a critical gap in treatment for the progressive eye disease. Results f
- Oculis to Provide Update on DIAMOND Phase 3 Program for OCS-01 Eye Drops at Innovate Retina and Eyecelerator 2024https://modernod.com/news/oculis-to-provide-update-on-diamond-phase-3-program-for-ocs-01-eye-drops-at-innovate-retina-and-eyecelerator-2024/2482488/Oculis announced an update on its DIAMOND phase 3 program for OCS-01, a high-concentration dexamethasone eye drop formulated with OPTIREACH technology for the treatment for diabetic macular edema (DME). David Eichenbaum, MD, an expert in retina diseases, will present new insig
- 4DMT Announces Phase 2 PRISM Interim Results for Intravitreal 4D-150 in Wet AMDhttps://modernod.com/news/4dmt-announces-phase-2-prism-interim-results-for-intravitreal-4d-150-in-wet-amd/2482364/4D Molecular Therapeutics announced initial interim 24-week landmark data from the population extension cohort of the PRISM phase 2 clinical trial, which evaluated intravitreal 4D-150 in a broad wet AMD patient population. The data were presented by Raj K. Maturi, MD, at the A
- Opthea Welcomes International Retina Thought Leaders to Its Medical Advisory Boardhttps://modernod.com/news/opthea-welcomes-international-retina-thought-leaders-to-its-medical-advisory-board/2482361/Opthea announced the formation of its Medical Advisory Board, which will comprise of 10 retina thought leaders from countries around the world, including the US, Argentina, Australia, China, France, Germany, and Israel. Chaired by Arshad M. Khanani, MD, MA, FASRS, Chief Medica
- Oculis Announces Positive Results from Phase 3 Trial of Once Daily Treatment for Inflammation and Pain Following Cataract Surgeryhttps://modernod.com/news/oculis-announces-positive-results-from-phase-3-trial-of-once-daily-ocs-01-for-treatment-of-inflammation-and-pain-following-cataract-surgery/2482221/Oculis announced positive results from the phase 3 OPTIMIZE-1 trial of OCS-01 for the treatment of inflammation and pain following cataract surgery at the 2024 ASCRS annual meeting in Boston. Eric Donnenfeld, MD, presented the “Once Daily OCS-01, an OPTIREACH F
- Adverum Announces Positive Efficacy and Safety Data from LUNA Phase 2 Trial of Ixo-vec in Patients with Wet AMDhttps://modernod.com/news/adverum-biotechnologies-announces-positive-preliminary-efficacy-and-safety-data-from-luna-phase-2-trial-of-ixo-vec-in-patients-with-wet-amd/2482107/Adverum Biotechnologies announced preliminary safety and efficacy data from the ongoing LUNA phase 2 trial in patients with wet age-related macular degeneration (AMD). These data are being presented by Arshad Khanani, MD, today at the 47th Annual Meeting of the Macula Society. The presentation, t
- Opthea Names New Clinical and Regulatory Leadership Membershttps://modernod.com/news/opthea-names-new-clinical-and-regulatory-leadership-members/2482091/Opthea announced the appointment of Julie Clark, MD, MS, as Senior Vice President (SVP), Clinical Development; and Fang Li, PhD, RAC, as SVP, Regulatory Affairs, effective February 1, 2024. Dr. Clark and Dr. Li will report to Opthea Chief Executive Officer Frederic Guerard, PharmD,
- IntRIS Hosts ARCR Macular 2024 Meeting and Presents Interview With FDA’s Dr. Wiley Chambershttps://modernod.com/news/intris-hosts-arcr-macular-2024-meeting-and-presents-interview-with-fdas-dr-wiley-chambers/2482057/The International Retinal Imaging Society (IntRIS) hosted the Atlantic Coast Retina Club (ACRC) Macula 2024, led by K. Bailey Freund, MD. According IntRIS, the ACRC meeting format includes rapid-fire single-case presentations, engaging discussions, and conferences covering diverse retin
- New "Eye Chart" App Designed to Address Common Challenges in Near Vision Testinghttps://modernod.com/news/new-eye-chart-app-designed-to-address-common-challenges-in-near-vision-testing/2481995/A new app aims to address common challenges encountered in near vision testing. The "Eye Chart" app, which was developed by Michael Ullman, MD, a cornea specialist at Ullman Eye Consultants in Pensacola, Florida, leverages the iPhone's TrueDepth camera to me
- Nanoscope Therapeutics Wins 'Best of Show' Award at AAO Eyecelerator 2023https://modernod.com/news/nanoscope-therapeutics-wins-best-of-show-award-at-aao-eyecelerator-2023/2481955/Nanoscope Therapeutics was awarded the 'Best of Show in Retina' award at this year's American Academy of Ophthalmology (AAO) Eyecelerator conference held in San Francisco on Thursday, November 2, 2023. During the conference, Samuel Barone, MD, Nanoscope's chief